Our findings confirmed aberrant BCLX mRNA splicing as a potential therapeutic target for GBM, and regulation of BCLX pre-mRNA splicing by SSOs is a novel approach to inhibit glioblastoma tumorigenesis alone or in combination with radiotherapy. The gene discussed is BCL2L1; the disease is glioblastoma.